Viatris Inc.

VTRSsupplier

Viatris is a global pharmaceutical company formed from the 2020 merger of Mylan and Pfizer's Upjohn division, focused on expanding access to generic and biosimilar medicines worldwide.

⇄ Compare

產品與營收

產品營收佔比

營收結構 ($15.0B)

靜態數據（加載即時財務…）

Developed Markets (45%)

Emerging Markets (30%)

Greater China (12%)

JANZ (Japan, Australia, NZ) (13%)

業務部門構成與主要客戶

產品詳情

Branded Generics35%

Off-patent branded drugs sold primarily in emerging markets

Complex Generics & Biosimilars25%

Biosimilar versions of Humira, Herceptin, and complex injectables

Generic Pharmaceuticals25%

Standard generic drugs for developed markets

Legacy Brands (Lipitor, EpiPen)15%

Heritage branded products from Pfizer Upjohn and Mylan

供應鏈關係

合作夥伴

Pfizer Inc.

Legacy Pfizer Upjohn product portfolio

影響: Medium — spun off from Pfizer

競爭對手

AbbVie Inc.

Biosimilar Humira competition

影響: Medium — biosimilar erosion of Humira

主要客戶

Walgreens Boots Alliance

Generic drug retail distribution

影響: Medium — pharmacy channel

宏觀與市場背景

제약 / 바이오行業新聞

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

近期催化劑

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

AI 分析

點擊「取得 AI 分析」以獲得 Viatris Inc. 的 AI 供應鏈分析。

企業資訊

總部

Canonsburg, Pennsylvania, USA

成立時間

2020

員工人數

37,000+

官網

viatris.com

行業概況 — 제약 / 바이오

行業新聞